Increase in PPI Utilization:
The total utilization of PPIs has significantly increased, almost tripling between 2009 and 2020.1
Physicians prescribe PPIs with similar frequency based on their own decisions and when following the recommendation of another specialist.1
Approximately 46% of patients have been on PPI therapy for more than 6 months.1
Challenges in Treating EE with PPIs:
Despite 8-week double-dose PPI therapies, around 10%–15% of patients with EE do not achieve complete mucosal healing and symptom control.2
The lack of sufficient acid inhibition by PPI, persistent non-acid reflux, reflux sensitivity, and non-GERD causes may contribute to this incomplete response.2
Edge of VONOprazan in PPI-Resistant EE:
VONOprazan has shown the ability to inhibit gastric acid secretion over a 24-hour period, with a significant increase in gastric pH 4 HTR.2
VONOprazan completely healed mucosal erosions at 8 weeks in more than 60% of PPI-resistant EE patients.2
Esophageal mucosal breaks were successfully treated in 87.5% of patients, with significant relief in GERD symptoms (as measured by the Frequency Scale for the Symptoms of GERD) within 4 weeks.2
Additionally, mucosal healing was maintained in 79.5% of patients at week 8, 86% at week 24, and 87.9% at week 48.3
Clinical trials show VONOprazan is non-inferior to conventional PPIs and may offer a novel option for managing higher-grade or PPI-resistant EE.2
In the past month, have you prescribed VONOprazan for patients with moderate to severe GERD or erosive esophagitis who reported persistent NAB despite PPI treatment?
Vono 20-Always on Duty
Vono, containing Vonoprazan molecule, is a Potassium Competitive Acid Blocker which helps in treatment of Refractory GERD, Erosive Esophagitis, H.Pylori, Gastric & Duodenal Ulcers
